A Cost-Utility Analysis of SQ^® Tree SLIT-Tablet versus Placebo in the Treatment of Birch Pollen Allergic Rhinitis from a Swedish Societal Perspective

References

• European Academy of Allergy and Clinical Immunology (EAACI). Global atlas of allergic rhinitis and chronic rhinosinusitis; 2015.
   Google Scholar
• Léger D, Annesi-Maesano I, Carat F, et al. Allergic rhinitis and its consequences on quality of sleep: an unexplored area. Arch Intern Med. 2006;166(16):1744–1748. doi:10.1001/archinte.166.16.1744
   PubMedGoogle Scholar
• Feng CH, Miller MD, Simon RA. The united allergic airway: connections between allergic rhinitis, asthma, and chronic sinusitis. Am J Rhinol Allergy. 2012;26(3):187–190. doi:10.2500/ajra.2012.26.3762
   PubMed Web of Science ®Google Scholar
• Khan DA. Allergic rhinitis and asthma: epidemiology and common pathophysiology. Allergy Asthma Proc. 2014;35(5):357–361. doi:10.2500/aap.2014.35.3794
   PubMed Web of Science ®Google Scholar
• Leynaert B, Neukirch C, Kony S, et al. Association between asthma and rhinitis according to atopic sensitization in a population-based study. J Allergy Clin Immunol. 2004;113(1):86–93. doi:10.1016/j.jaci.2003.10.010
   PubMed Web of Science ®Google Scholar
• Linneberg A, Henrik Nielsen N, Frølund L, Madsen F, Dirksen A, Jørgensen T; Copenhagen Allergy Study. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy. 2002;57(11):1048–1052. doi:10.1034/j.1398-9995.2002.23664.x
   PubMed Web of Science ®Google Scholar
• Fiocchi A, Fox AT. Preventing progression of allergic rhinitis: the role of specific immunotherapy. Arch Dis Child Educ Pract Ed. 2011;96(3):91–100. doi:10.1136/adc.2010.183095
   PubMed Web of Science ®Google Scholar
• Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol. 2002;109(3):419–425. doi:10.1067/mai.2002.121701
   PubMed Web of Science ®Google Scholar
• Polosa R, Al-Delaimy WK, Russo C, Piccillo G, Sarvà M. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res. 2005;6:153. doi:10.1186/1465-9921-6-153
   PubMed Web of Science ®Google Scholar
• Shaaban R, Zureik M, Soussan D, et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008;372(9643):1049–1057. doi:10.1016/S0140-6736(08)61446-4
   PubMed Web of Science ®Google Scholar
• World Allergy Organization. WAO white book on allergy. Milwaukee, WI, USA: World Allergy Organization; 2013. Available from: https://www.worldallergy.org/UserFiles/file/WhiteBook2-2013-v8.pdf. Accessed January 10, 2022..
   Google Scholar
• Biedermann T, Winther L, Till SJ, Panzner P, Knulst A, Valovirta E. Birch pollen allergy in Europe. Allergy. 2019;74(7):1237–1248. doi:10.1111/all.13758
   PubMed Web of Science ®Google Scholar
• Morjaria JB, Caruso M, Emma R, Russo C, Polosa R. Treatment of Allergic rhinitis as a strategy for preventing asthma. Curr Allergy Asthma Rep. 2018;18(4):23. doi:10.1007/s11882-018-0781-y
   PubMed Web of Science ®Google Scholar
• Eriksson J, Ekerljung L, Rönmark E, et al. Update of prevalence of self-reported allergic rhinitis and chronic nasal symptoms among adults in Sweden. Clin Respir J. 2012;6(3):159–168. doi:10.1111/j.1752-699X.2011.00269.x
   PubMed Web of Science ®Google Scholar
• Lorenz AR, Lüttkopf D, May S, Scheurer S, Vieths S. The principle of homologous groups in regulatory affairs of allergen products – a proposal. Int Arch Allergy Immunol. 2008;148(1):1–17. doi:10.1159/000151243
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on allergen products: production and quality issues. EMEA/CHMP/BWP/304831/2007. London, UK; 2008. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-allergen-products-production-quality-issues_en.pdf. Accessed January 10, 2022..
   Google Scholar
• D’Amato G, Cecchi L, Bonini S, et al. Allergenic pollen and pollen allergy in Europe. Allergy. 2007;62(9):976–990. doi:10.1111/j.1398-9995.2007.01393.x
   PubMed Web of Science ®Google Scholar
• Integrated Clinical Trial Report. Efficacy and safety of the SQ tree SLIT-tablet in subjects with moderate to severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch group. Trial ID: TT-04, 16 January 2018; 2018.
   Google Scholar
• Biedermann T, Kuna P, Panzner P, et al. The SQ tree SLIT-tablet is highly effective and well tolerated: results from a randomized, double-blind, placebo-controlled Phase III trial. J Allergy Clin Immunol. 2019;143(3):1058–1066.e6. doi:10.1016/j.jaci.2018.12.1001
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. World Health Organization; GA(2)LEN; AllerGen. allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160. doi:10.1111/j.1398-9995.2007.01620.x
   PubMed Web of Science ®Google Scholar
• Farmaceutiska Specialiteter i Sverige. ITULAZAX Summary of product characteristics. Available from: https://www.fass.se/LIF/product?userType=2&nplId=20180727000034&docType=6. Accessed May 9, 2022.
   Google Scholar
• Linneberg A, Dam Petersen K, Hahn-Pedersen J, Hammerby E, Serup-Hansen N, Boxall N. Burden of allergic respiratory disease: a systematic review. Clin Mol Allergy. 2016;14:12. doi:10.1186/s12948-016-0049-9
   PubMedGoogle Scholar
• Cardell LO, Olsson P, Andersson M, et al. TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study. NPJ Prim Care Respir Med. 2016;26:15082. doi:10.1038/npjpcrm.2015.82
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exper Allergy. 1991;21:77–83. doi:10.1111/j.1365-2222.1991.tb00807.x
   PubMed Web of Science ®Google Scholar
• Dick K, Briggs A, Ohsfeldt R, Sydendal Grand T, Buchs S. A quality-of-life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. J Med Econ. 2020;23(1):64–69. doi:10.1080/13696998.2019.1649268
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health. 2011;14:539–545. doi:10.1016/j.jval.2010.10.029
   PubMed Web of Science ®Google Scholar
• Hahn-Pedersen J, Worm M, Green W, Nørgaard Andreasen J, Taylor M. Cost utility analysis of the SQ® HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting. Clin Transl Allergy. 2016;6:35. doi:10.1186/s13601-016-0127-6
   PubMed Web of Science ®Google Scholar
• Verheggen BG, Westerhout KY, Schreder CH, Augustin M. Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany. Clin Transl Allergy. 2015;5:1. doi:10.1186/s13601-015-0045-z
   PubMed Web of Science ®Google Scholar
• Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy. 2008;63(12):1624–1629. doi:10.1111/j.1398-9995.2008.01743.x
   PubMed Web of Science ®Google Scholar
• Ronaldson S, Taylor M, Bech PG, Shenton R, Bufe A. Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax) in children. Clinicoeconom Outcomes Res. 2014;6(1):187–196.
   PubMedGoogle Scholar
• European Academy of Allergy and Clinical Immunology (EAACI). Allergen Immunotherapy guidelines. Part 2: recommendations. Available from: https://medialibrary.eaaci.org/mediatheque/media.aspx?mediaId=60223&channel=8518. Accessed January 12, 2022.
   Google Scholar
• Jacobsen L, Niggemann B, Dreborg S, et al.; The PAT investigator group. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943–948. doi:10.1111/j.1398-9995.2007.01451.x
   PubMed Web of Science ®Google Scholar
• Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy. 1988;43(7):523–529. doi:10.1111/j.1398-9995.1988.tb01631.x
   PubMed Web of Science ®Google Scholar
• Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy. 1996;51(6):430–433. doi:10.1111/j.1398-9995.1996.tb04643.x
   PubMed Web of Science ®Google Scholar
• Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341(7):468–475. doi:10.1056/NEJM199908123410702
   PubMed Web of Science ®Google Scholar
• Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy. 2009;64(1):179–186. doi:10.1111/j.1398-9995.2008.01875.x
   PubMedGoogle Scholar
• Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010;126(5):969–975. doi:10.1016/j.jaci.2010.08.030
   PubMed Web of Science ®Google Scholar
• Tabar AI, Arroabarren E, Echechipía S, García BE, Martin S, Alvarez-Puebla MJ. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol. 2011;127(1):57–63. doi:10.1016/j.jaci.2010.10.025
   PubMed Web of Science ®Google Scholar
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717–725.e5. doi:10.1016/j.jaci.2011.12.973
   PubMed Web of Science ®Google Scholar
• Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;133(6):1608–1614. doi:10.1016/j.jaci.2013.11.012
   PubMed Web of Science ®Google Scholar
• Didier A, Malling HJ, Worm M, Horak F, Sussman GL. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clin Transl Allergy. 2015;5:12. doi:10.1186/s13601-015-0057-8
   PubMed Web of Science ®Google Scholar
• Scadding GW, Calderon MA, Shamji MH, et al.; Immune Tolerance Network GRASS Study Team. Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial. JAMA. 2017;317(6):615–625. doi:10.1001/jama.2016.21040
   PubMed Web of Science ®Google Scholar
• Bozek A, Starczewska-Dymek L, Jarzab J. Prolonged effect of allergen sublingual immunotherapy for house dust mites in elderly patients. Ann Allergy Asthma Immunol. 2017;119(1):77–82. doi:10.1016/j.anai.2017.05.012
   PubMed Web of Science ®Google Scholar
• Valovirta E, Petersen TH, Piotrowska T, et al.; GAP investigators. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529–538. doi:10.1016/j.jaci.2017.06.014
   PubMed Web of Science ®Google Scholar
• Yonekura S, Gotoh M, Kaneko S, Maekawa Y, Okubo K, Okamoto Y. Disease-modifying effect of Japanese cedar pollen sublingual immunotherapy tablets. J Allergy Clin Immunol Pract. 2021;9(11):4103–4116.e14. doi:10.1016/j.jaip.2021.06.060
   PubMed Web of Science ®Google Scholar
• Dental and Pharmaceutical Benefits Board. Ändring i Tandvårds- och läkemedelsförmånsverkets allmänna råd (TLVAR 2003:2) om ekonomiska utvärderingar. Available from: https://www.tlv.se/download/18.467926b615d084471ac3230c/1510316374332/TLVAR_2017_1.pdf. Accessed September 6, 2018.
   Google Scholar
• Svensson M, Nilsson FO, Arnberg K. Reimbursement decisions for pharmaceuticals in Sweden: the Impact of disease severity and cost effectiveness. Pharmacoeconomics. 2015;33(11):1229–1236. doi:10.1007/s40273-015-0307-6
   PubMed Web of Science ®Google Scholar
• Statistiska centralbyrån. National Accounts, quarterly and annual estimates; 2021. Available from: https://www.scb.se/en/finding-statistics/statistics-by-subject-area/national-accounts/national-accounts/national-accounts-quarterly-and-annual-estimates/. Accessed January 12, 2022.
   Google Scholar
• Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1–55. doi:10.1016/j.jaci.2010.09.034
   PubMed Web of Science ®Google Scholar
• Greenhawt M, Oppenheimer J, Nelson M, et al. Sublingual immunotherapy: a focused allergen immunotherapy practice parameter update. Ann Allergy Asthma Immunol. 2017;118(3):276–282.e2. doi:10.1016/j.anai.2016.12.009
   PubMed Web of Science ®Google Scholar
• Eurostat. Unemployment by sex and age - monthly average. Sweden; 2021. Available from: http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=une_rt_m&lang=en. Accessed January 12, 2022.
   Google Scholar
• Statistiska centralbyrån. Short-term statistics, wages and salaries, private sector (KLP); 2022. Available from: http://www.scb.se/am0101-en. Accessed January 12, 2022.
   Google Scholar
• Allam JP, Andreasen JN, Mette J, Serup-Hansen N, Wüstenberg EG. Comparison of allergy immunotherapy medication persistence with a sublingual immunotherapy tablet versus subcutaneous immunotherapy in Germany. J Allergy Clin Immunol. 2018;141(5):1898–1901.e5. doi:10.1016/j.jaci.2017.12.999
   PubMed Web of Science ®Google Scholar
• Geroldinger-Simic M, Zelniker T, Aberer W, et al. Birch pollen-related food allergy: clinical aspects and the role of allergen-specific IgE and IgG4 antibodies. J Allergy Clin Immunol. 2011;127(3):616–22.e1. doi:10.1016/j.jaci.2010.10.027
   PubMed Web of Science ®Google Scholar
• Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective. Clin Exp Allergy. 2007;37(5):772–779. doi:10.1111/j.1365-2222.2007.02706.x
   PubMed Web of Science ®Google Scholar